EBFI Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

被引：0
|
作者：
Escherich, Carolin S. [1 ]
Li, Zhenhua [2 ]
Barnett, Kelly R. [1 ]
Li, Yizhen [1 ]
Walker, Megan [1 ]
Yang, Wenjian [2 ]
Huang, Xin [1 ]
Yu, Jiyang [1 ]
Stock, Wendy [3 ]
Paietta, Elisabeth [4 ]
Konopleva, Marina [5 ]
Kornblau, Steven M. [6 ]
Litzow, Mark R. [7 ]
Inaba, Hiroto [1 ]
Pui, Ching-Hon [1 ]
Loh, Mignon L. [8 ]
Savic, Daniel [1 ]
Yang, Jun J. [1 ]
机构：
[1] St Jude Childrens Res Hosp, Memphis, TN USA
[2] St Jude Childrens Res Hosp, Dept Pharm & Pharmaceut Sci, Memphis, TN USA
[3] Univ Chicago, Chicago, IL USA
[4] Montefiore Med Ctr, Dept Oncol, Bronx, NY USA
[5] Albert Einstein Coll Med, Bronx, NY USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[7] Mayo Clin, Div Hematol, Rochester, MN USA
[8] Univ Washington, Seattle Childrens Hosp, Ben Towne Ctr Childhood Canc Res, Fred Hutch Canc Ctr, Seattle, WA USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198800
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：830 / 831
页数：2
相关论文
共 50 条
  • [21] Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin
    Jabbour, Elias
    Advani, Anjali S.
    Stelljes, Matthias
    Stock, Wendy
    Liedtke, Michaela
    Goekbuget, Nicola
    Martinelli, Giovanni
    O'Brien, Susan
    White, Jane Liang
    Wang, Tao
    Paccagnella, M. Luisa
    Sleight, Barbara
    Vandendries, Erik
    DeAngelo, Daniel J.
    Kantarjian, Hagop M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (04) : 408 - 416
  • [22] Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Deepa Bhojwani
    Richard Sposto
    Nirali N. Shah
    Vilmarie Rodriguez
    Constance Yuan
    Maryalice Stetler-Stevenson
    Maureen M. O’Brien
    Jennifer L. McNeer
    Amrana Quereshi
    Aurelie Cabannes
    Paul Schlegel
    Claudia Rossig
    Luciano Dalla-Pozza
    Keith August
    Sarah Alexander
    Jean-Pierre Bourquin
    Michel Zwaan
    Elizabeth A. Raetz
    Mignon L. Loh
    Susan R. Rheingold
    Leukemia, 2019, 33 : 1061 - 1062
  • [23] Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
    DeAngelo, Daniel J.
    Advani, Anjali S.
    Marks, David, I
    Stelljes, Matthias
    Liedtke, Michaela
    Stock, Wendy
    Goekbuget, Nicola
    Jabbour, Elias
    Merchant, Akil
    Wang, Tao
    Vandendries, Erik
    Neuhof, Alexander
    Kantarjian, Hagop
    O'Brien, Susan
    BLOOD CANCER JOURNAL, 2020, 10 (08)
  • [24] Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
    Luca Bertamini
    Jacopo Nanni
    Giovanni Marconi
    Mariachiara Abbenante
    Valentina Robustelli
    Francesco Bacci
    Antonella Matti
    Stefania Paolini
    Chiara Sartor
    Silvia Lo Monaco
    Maria Chiara Fontana
    Stefano De Polo
    Michele Cavo
    Antonio Curti
    Giovanni Martinelli
    Cristina Papayannidis
    BMC Cancer, 18
  • [25] Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
    Daniel J. DeAngelo
    Anjali S. Advani
    David I. Marks
    Matthias Stelljes
    Michaela Liedtke
    Wendy Stock
    Nicola Gökbuget
    Elias Jabbour
    Akil Merchant
    Tao Wang
    Erik Vandendries
    Alexander Neuhof
    Hagop Kantarjian
    Susan O’Brien
    Blood Cancer Journal, 10
  • [26] Pediatric Studies with Inotuzumab Ozogamicin for B-cell Acute Lymphoblastic Leukemia
    Pennesi, Edoardo
    TURKISH JOURNAL OF HEMATOLOGY, 2023, 40 : 8 - 11
  • [27] Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
    Uy, Natalie
    Nadeau, Michelle
    Stahl, Maximilian
    Zeidan, Amer M.
    JOURNAL OF BLOOD MEDICINE, 2018, 9 : 67 - 74
  • [28] Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia
    Tinajero, Jose
    Koller, Paul
    Ali, Haris
    LEUKEMIA RESEARCH, 2023, 129
  • [29] Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
    Bertamini, Luca
    Nanni, Jacopo
    Marconi, Giovanni
    Abbenante, Mariachiara
    Robustelli, Valentina
    Bacci, Francesco
    Matti, Antonella
    Paolini, Stefania
    Sartor, Chiara
    Lo Monaco, Silvia
    Fontana, Maria Chiara
    De Polo, Stefano
    Cavo, Michele
    Curti, Antonio
    Martinelli, Giovanni
    Papayannidis, Cristina
    BMC CANCER, 2018, 18
  • [30] Inotuzumab Ozogamicin: First Global Approval
    Yvette N. Lamb
    Drugs, 2017, 77 : 1603 - 1610
12345